Financials data is unavailable for this security.
View more
Year on year Immunoprecise Antibodies Ltd grew revenues 18.65% from 20.67m to 24.52m while net income improved from a loss of 26.56m to a smaller loss of 27.18m.
Gross margin | 48.21% |
---|---|
Net profit margin | -114.58% |
Operating margin | -123.33% |
Return on assets | -40.63% |
---|---|
Return on equity | -63.68% |
Return on investment | -46.68% |
More ▼
Cash flow in CADView more
In 2024, cash reserves at Immunoprecise Antibodies Ltd fell by 4.82m. Cash Flow from Financing totalled 1.02m or 4.16% of revenues. In addition the company used 4.25m for operations while cash used for investing totalled 1.56m.
Cash flow per share | -0.6189 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.8876 |
---|---|
Tangible book value per share | 0.0428 |
More ▼
Balance sheet in CADView more
Current ratio | 0.9862 |
---|---|
Quick ratio | 0.8189 |
Total debt/total equity | 0.49 |
---|---|
Total debt/total capital | 0.3289 |
More ▼